報價延遲最少15分鐘:2025/05/13 20:35 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.06 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.57/-0.45
|
|
企業價值
4.99M
|
| 資產負債 |
|
每股賬面淨值
3.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.50M
|
|
每股收益
1.40
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 20:35 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. |